| Asthma
Advair HFA vs Rayos
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Advair Hfa vs Rayos with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRayos has a higher rate of injection site reactions vs Advair Hfa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rayos but not Advair Hfa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Advair Hfa
Rayos
At A Glance
Oral inhalation
Twice daily
ICS/LABA combination
Oral
Daily
Corticosteroid
Indications
- Asthma
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
Dosing
Asthma 2 oral inhalations (45 mcg/21 mcg, 115 mcg/21 mcg, or 230 mcg/21 mcg) twice daily approximately 12 hours apart; starting strength based on asthma severity; maximum 2 inhalations of 230 mcg/21 mcg twice daily.
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required
- Hypersensitivity to any ingredient of ADVAIR HFA
- Known hypersensitivity to prednisone or any excipient
Adverse Reactions
Most common (>=3%) Upper respiratory tract infection, throat irritation, headache, nausea and vomiting, musculoskeletal pain, upper respiratory inflammation, viral respiratory infection, hoarseness/dysphonia, dizziness, viral gastrointestinal infection, gastrointestinal signs and symptoms, muscle pain
Serious Serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia in COPD patients, immunosuppression and risk of infections, hypercorticism and adrenal suppression, cardiovascular and CNS effects, reduction in bone mineral density, growth effects, glaucoma and cataracts
Postmarketing Arrhythmias, hypertension, ventricular tachycardia, Cushing's syndrome, osteoporosis, cataracts, glaucoma, anaphylaxis, esophageal candidiasis, paradoxical bronchospasm, agitation, depression
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Pharmacology
ADVAIR HFA combines fluticasone propionate, a synthetic trifluorinated corticosteroid with broad anti-inflammatory activity via glucocorticoid receptor binding, and salmeterol, a selective long-acting beta2-adrenoceptor agonist (LABA) that relaxes bronchial smooth muscle by stimulating adenyl cyclase to increase cyclic AMP levels.
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Advair Hfa
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (12/12)
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
UnitedHealthcare
Advair Hfa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (5/8)
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Advair Hfa
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Advair Hfa.
No savings programs available for Rayos.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Advair HfaView full Advair Hfa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.